Research programme: bone disease peptide therapeutics - Alize Pharma III SAS

Drug Profile

Research programme: bone disease peptide therapeutics - Alize Pharma III SAS

Alternative Names: I-HBD1 analogs - Alize Pharma III SAS

Latest Information Update: 29 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Maine; University of North Carolina at Chapel Hill
  • Developer Alize Pharma III SAS; New Paradigm Therapeutics
  • Class Peptides
  • Mechanism of Action Insulin-like growth factor binding protein 2 modulators; Osteoblast stimulants; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Osteoporosis; Postmenopausal osteoporosis

Most Recent Events

  • 01 May 2016 Preclinical trials in Postmenopausal osteoporosis in USA (Parenteral)
  • 04 Dec 2014 Preclinical trials in Osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top